Stay up-to-date with the Sun Pharma Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on ...

Welcome to the Sun Pharma Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock.

After a US Court blocked the launch of Leqselvi, a drug used to treat severe alopecia areata, shares of Sun Pharma plunged ...

Thirty out of the 41 analysts tracking the company have a 'buy' rating on the stock, seven suggest a 'hold' and four have a ...

Most brokerages retained ratings and target prices for Sun Pharmaceutical Industries after its second quarter earnings beat ...

Earlier on Monday, Sun Pharma reported a 28 per cent increase in its consolidated net profit to Rs 3,040 crore in Q2 FY2025.

According to Citi, the delay in the launch of Sun Pharma's alopecia areata drug, Leqselvi, could impact its near-term ...

In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.

Led by growth in its domestic business, the specialty generic pharma company is expected to post good July-September quarter.

Zen Technologies Q2 profit zooms 365% YoY to Rs 63 crore with robust growth in revenue, operating numbers. Hero MotoCorp's ...

Sun Pharmaceuticals Ltd., the country's largest drugmaker, on Monday (October 28), reported a net profit of ₹3,040 crore, ...